Skip to content
10-Q

Quarterly Report

Processa Pharmaceuticals, Inc. PCSA

0001493152-26-021721

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 2.75M sh
Shares Diluted Q1 2026 · Mar 31, 2026 2.62M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 373.97K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.59M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.73M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.69M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $5.54M
Stockholders Equity Q1 2026 · Mar 31, 2026 $2.54M
Stockholders Equity Q1 2026 · Dec 31, 2025 $5.58M
Stockholders Equity Q1 2026 · Mar 31, 2025 $3.53M
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.7M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.98M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.24M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.98M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.24M
Current Assets Q1 2026 · Mar 31, 2026 $1.94M
Current Assets Q1 2026 · Dec 31, 2025 $5.67M
Total Assets Q1 2026 · Mar 31, 2026 $4.52M
Total Assets Q1 2026 · Dec 31, 2025 $7.81M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.29
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$7.58
Eps Basic Q1 2026 · Mar 31, 2026 −$1.29
Eps Basic restated Q1 2026 · Mar 31, 2025 −$7.58
Net Income Q1 2026 · Mar 31, 2026 −$3.38M
Net Income Q1 2026 · Mar 31, 2025 −$2.83M
Operating Income Q1 2026 · Mar 31, 2026 −$3.33M
Operating Income Q1 2026 · Mar 31, 2025 −$2.85M
Stock Issued Q1 2026 · Feb 17, 2026 86.96K sh